Morpholinylquinazolines
    1.
    发明授权
    Morpholinylquinazolines 有权
    吗啉基喹唑啉

    公开(公告)号:US09126952B2

    公开(公告)日:2015-09-08

    申请号:US13581699

    申请日:2011-02-17

    摘要: The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W1, W2, L, A, Alk, Cyc, Ar, Het1, Het2, Hal and n have the meaning indicated in Claim 1, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.

    摘要翻译: 本发明涉及其中R1,R2,R3,R4,Y,W1,W2,L,A,Alk,Cyc,Ar,Het1,Het2,Hal等式(I),(II)和(III) 和n具有权利要求1所述的含义,和/或其生理上可接受的盐,互变异构体和立体异构体,包括其所有比例的混合物。 式(I)的化合物可用于抑制丝氨酸/苏氨酸蛋白激酶和癌细胞对抗癌剂和/或电离辐射的敏化。 本发明还涉及结合放射治疗和/或抗癌剂的式(I)化合物在癌症,肿瘤,转移或血管生成障碍的预防,治疗或进展控制中的用途。 本发明还涉及通过式(II)和(III)化合物的反应制备式(I)化合物的方法,并且任选地转化式(I)化合物的碱或酸, 成为他们的一种盐。